Acc 22: Results From The Empulse Study - Empagliflozin Proves Beneficial For Patients With Hf

ACC 22: Results from the EMPULSE Study - Empagliflozin Proves Beneficial for Patients with HF

EMPULSE Results

AHA 22: EMPEROR-POOLED: Clinical Outcomes & Efficacy of Empagliflozin in Black vs White Pts With HF

EMPULSE Trial. EMPAGLIFLOZIN in Acute Heart Failure. AHA2021

ESC TV at #AHA21 - Expert Perspectives on the EMPULSE Trial

European Society of Cardiology

ACC 22 Late-breaker Discussion: The PROMPT-HF Trial | with Dr Harriette Van Spall

ACC 22: Results from the PACIFIC AF Trial | Dr Manesh Patel

AHA 2021 Late-Breaker Discussion: The EMPULSE Trial

EMPULSE: The ‘missing link’ for empagliflozin in heart failure | Adriaan Voors

Medicine Matters diabetes

ESC 2022: The EMMY Trial: Empagliflozin in Patients with Acute MI | Prof Harald Sourji

ACC Cardiology Hour With Dr. Valentin Fuster | ACC.22 Day 1

American College of Cardiology

ACC 22: Results from the GIPS-IV Trial | Dr Marie-Sophie De Koning & Dr Pim van der Harst

ACC 22 Late-breaker Discussion: The DIAMOND Trial | with Dr Harriette Van Spall

ACC 22: Findings From the PARTITA Trial | Dr Paolo Della Bella

ACC 22: Results from the TRANSLATE-TIMI 70 Trial | Dr Brian Bergmark

ACC 22: Results from the POISE-3 Trial | Dr Philip J Devereaux

ACC 22: FAME 3 Suggests CABG Outperforms FFR-Guided PCI in Patients with Multivessel Disease

ACC 22: 5 Trials That Will Change Your Practice with Dr Mirvat Alasnag

ACC 22: Results from a sub-study of the POISE-3 Trial | Dr Maura Marcucci